OptimizeRx (NASDAQ:OPRX) Stock Rating Upgraded by B. Riley

OptimizeRx (NASDAQ:OPRX) was upgraded by research analysts at B. Riley to a “strong-buy” rating in a report issued on Wednesday, Marketbeat Ratings reports.

Several other equities analysts also recently commented on the company. Stifel Nicolaus decreased their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. William Blair reissued an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Barclays reduced their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. JMP Securities reissued a “market outperform” rating and set a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Price Performance

OptimizeRx stock opened at $7.15 on Wednesday. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $14.13. The stock’s 50 day moving average is $5.44 and its 200-day moving average is $5.93. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $131.71 million, a price-to-earnings ratio of -5.38 and a beta of 1.31.

Institutional Investors Weigh In On OptimizeRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new stake in OptimizeRx during the fourth quarter worth $25,000. BNP Paribas Financial Markets lifted its stake in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. SG Americas Securities LLC bought a new stake in OptimizeRx during the fourth quarter worth $51,000. Wells Fargo & Company MN lifted its stake in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after purchasing an additional 2,797 shares during the last quarter. Finally, Quest Partners LLC lifted its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.